Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Return on Capital Employed (2018 - 2025)

Historic Return on Capital Employed for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Q3 2025 value amounting to 0.41%.

  • Crinetics Pharmaceuticals' Return on Capital Employed fell 600.0% to 0.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.41%, marking a year-over-year decrease of 600.0%. This contributed to the annual value of 0.35% for FY2024, which is 1500.0% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Return on Capital Employed is 0.41%, which was down 600.0% from 0.34% recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Return on Capital Employed peaked at 0.28% during Q1 2025, and registered a low of 0.71% during Q2 2023.
  • For the 5-year period, Crinetics Pharmaceuticals' Return on Capital Employed averaged around 0.41%, with its median value being 0.39% (2021).
  • In the last 5 years, Crinetics Pharmaceuticals' Return on Capital Employed plummeted by -3200bps in 2023 and then skyrocketed by 4000bps in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.39% in 2021, then dropped by -26bps to 0.49% in 2022, then increased by 24bps to 0.37% in 2023, then grew by 20bps to 0.3% in 2024, then plummeted by -36bps to 0.41% in 2025.
  • Its last three reported values are 0.41% in Q3 2025, 0.34% for Q2 2025, and 0.28% during Q1 2025.